Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-α and ribavirin

被引：0
作者：
Elikowski, Waldemar [1 ]
Malek, Malgorzata [1 ]
Kurosz, Jolanta [2 ]
Bereszynska, Iwona [3 ]
Marszalek, Andrzej [4 ]
Zawilska, Krystyna [5 ]
Mozer-Lisewska, Iwona [4 ,6 ]
机构：
[1] Szpital J Strusia, Oddzial Chorob Wewnetrznych, PL-61285 Poznan, Poland
[2] Szpital J Strusia, Pracownia Hemostazy, PL-61285 Poznan, Poland
[3] ZOZ Poznan Stare Miasto, Poradnia Chorob Watroby, Poznan, Poland
[4] Szpital J Strusia, Oddzial Chorob Zakaznych, PL-61285 Poznan, Poland
[5] Szpital J Strusia, Oddzial Chorob Wewnetrznych & Hematol, PL-61285 Poznan, Poland
[6] Uniwersytet Med, Katedra & Klin Chorob Zakaznych, Poznan, Poland
来源：
KARDIOLOGIA POLSKA | 2010年 / 68卷 / 11期
关键词：
pulmonary embolism; interferon-alpha; ribavirin; chronic hepatitis C; VENOUS THROMBOEMBOLISM; CUTANEOUS NECROSIS; PLUS RIBAVIRIN; PATIENT; COMBINATION; INJECTION; FIBROSIS; PROTEIN; VIRUS; RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The authors described a case of a 30 year-old man with chronic hepatitis C (G1,S1) complicated by pulmonary embolism (PE), preceded by symptoms of respiratory system infection, which occurred after 6 months of combination therapy with pegylated interferon-a and ribavirin. Right sided nonbacterial thrombotic endocarditis as a source of segmental/subsegmental PE was found. Hemostatic work up showed increased activated protein C resistance, elevated factor VIII activity and fibrinogen concentration as well as hyperhomocysteinaemia (all these disturbances returned to normal 3-6 months later). The patient's clinical status improved during anticoagulation therapy. Antiviral treatment was not continued as virological response was achieved.
引用
收藏
页码：1261 / 1265
页数：5
相关论文
共 50 条
  • [21] Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C
    Ishiguro, Haruya
    Abe, Hiroshi
    Seki, Nobuyoshi
    Sugita, Tomonori
    Aida, Yuta
    Itagaki, Munenori
    Sutoh, Satoshi
    Shimada, Noritomo
    Furihata, Tomomi
    Tsubota, Akihito
    Aizawa, Yoshio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (13) : 3904 - 3911
  • [22] Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C
    Bergamini, A
    Bolacchi, F
    Cepparulo, M
    Demin, F
    Uccella, I
    Bongiovanni, B
    Ombres, D
    Angelico, F
    Liuti, A
    Hurtova, M
    Francioso, S
    Carvelli, C
    Cerasari, G
    Angelico, M
    Rocchi, G
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (03) : 459 - 464
  • [23] Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C
    Chew, Kara W.
    Allen, Scott A.
    Taylor, Lynn E.
    Rich, Josiah D.
    Feller, Edward
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (07) : 686 - 691
  • [24] Pegylated interferon a and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients
    Pawelczyk, Tomasz
    Pawelczyk, Agnieszka
    Strzelecki, Dominik
    Rabe-Jablonska, Jolanta
    GENERAL HOSPITAL PSYCHIATRY, 2008, 30 (06) : 501 - 508
  • [25] Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Leung, Yvette
    Urbanski, Stefan J.
    Schindel, Lynn
    Myers, Robert P.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (10) : 661 - 663
  • [26] Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C
    Brochot, Etienne
    Riachi, Ghassan
    Plantier, Jean-Christophe
    Guillemard, Catherine
    Vabret, Astrid
    Mathurin, Philippe
    Nguyen-Khac, Eric
    Duverlie, Gilles
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (07) : 1191 - 1198
  • [27] Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation
    Li, Ling-Fei
    Shi, Ke-Qing
    Lin, Yi-Qian
    Wang, Li-Ren
    He, Jiang-Ping
    Braddock, Martin
    Chen, Yong-Ping
    Zheng, Ming-Hua
    GENE, 2014, 544 (02) : 101 - 106
  • [28] Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients
    Frei, Pascal
    Leucht, Anna-Kathrin
    Held, Ulrike
    Kofmehl, Reto
    Manser, Christine N.
    Schmitt, Johannes
    Mertens, Joachim
    Rau, Monika
    Baur, Katharina
    Gerlach, Tilman
    Negro, Francesco
    Heim, Markus
    Moradpour, Darius
    Cerny, Andreas
    Dufour, Jean-Francois
    Muellhaupt, Beat
    Geier, Andreas
    LIVER INTERNATIONAL, 2014, 34 (04) : 551 - 557
  • [29] Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients
    Lee, Seok
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Lee, Chang Seop
    Choi, Chang Soo
    Cho, Eun Young
    Kim, Haak Cheoul
    INTERVIROLOGY, 2010, 53 (03) : 146 - 153
  • [30] Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
    Garib, Junia Rios
    Garcia, Guilherme Freire
    Teixeira, Rosangela
    Lima e Silva, Francisco das Chagas
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (08) : 625 - 631
12345